Capmatinib (Tabrecta) is a targeted therapeutic agent that has demonstrated favorable efficacy in the treatment of specific types of non-small cell lung cancer (NSCLC) in recent years. As a kinase inhibitor, it exerts anti-cancer effects by precisely acting on MET gene mutations.

How Effective is Capmatinib (Tabrecta) in Treatment?

Therapeutic Efficacy

Capmatinib has shown good therapeutic activity in patients with metastatic NSCLC positive for MET exon 14 skipping mutation.

By specifically inhibiting the activity of MET receptor tyrosine kinase, the drug blocks the transmission of downstream signaling pathways, thereby suppressing the proliferation and survival of tumor cells.

Indicated Population for Capmatinib (Tabrecta)

Requirements for Patient Status

Eligible patients should be adults, and their disease must be in the metastatic stage.

Prior to administration, professional genetic testing must be conducted to confirm the presence of the mutation—this is a key prerequisite for ensuring treatment effectiveness.

The drug has shown efficacy in both treatment-naive patients and previously treated patients; however, specific treatment regimens need to be developed based on individual patient conditions.

Precautions for Special Populations

For elderly patients, dose adjustment is generally not required, but close monitoring is necessary.

Patients with hepatic or renal impairment also require special attention. In particular, there is limited experience in using the drug in patients with severe renal impairment, so careful evaluation should be conducted.

The drug is contraindicated in pregnant women. Men and women of childbearing age must take effective contraceptive measures during treatment and for a certain period after discontinuing the drug.

Medication Monitoring for Capmatinib (Tabrecta)

Efficacy Monitoring

Regular imaging examinations to assess tumor changes are the main method for monitoring therapeutic efficacy.

Monitor changes in patient symptoms, such as improvements in symptoms like dyspnea and cough.

The patient's overall functional status and quality of life are also important indicators for evaluating therapeutic efficacy.

Safety Monitoring

Pulmonary monitoring: Be alert to the occurrence of interstitial lung disease (ILD)/pneumonitis. If new or worsening pulmonary symptoms appear, the patient should seek medical attention immediately for evaluation.

Hepatic function monitoring: Regular hepatic function tests are required before and during treatment, with more frequent monitoring especially in the first 3 months.

Other monitoring: Includes routine indicators such as renal function and electrolyte balance, as well as other adverse reactions that may be caused by the drug.